131 related articles for article (PubMed ID: 34197115)
1. Insights into the Protein Ruthenation Mechanism by Antimetastatic Metallodrugs: High-Resolution X-ray Structures of the Adduct Formed between Hen Egg-White Lysozyme and
Chiniadis L; Giastas P; Bratsos I; Papakyriakou A
Inorg Chem; 2021 Jul; 60(14):10729-10737. PubMed ID: 34197115
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme.
Messori L; Merlino A
Dalton Trans; 2014 Apr; 43(16):6128-31. PubMed ID: 24553967
[TBL] [Abstract][Full Text] [Related]
3. High-resolution crystal structures of a "half sandwich"-type Ru(II) coordination compound bound to hen egg-white lysozyme and proteinase K.
Chiniadis L; Bratsos I; Bethanis K; Karpusas M; Giastas P; Papakyriakou A
J Biol Inorg Chem; 2020 Jun; 25(4):635-645. PubMed ID: 32266561
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.
Casini A; Mastrobuoni G; Terenghi M; Gabbiani C; Monzani E; Moneti G; Casella L; Messori L
J Biol Inorg Chem; 2007 Nov; 12(8):1107-17. PubMed ID: 17680283
[TBL] [Abstract][Full Text] [Related]
5. Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu.
Vergara A; D'Errico G; Montesarchio D; Mangiapia G; Paduano L; Merlino A
Inorg Chem; 2013 Apr; 52(8):4157-9. PubMed ID: 23517183
[TBL] [Abstract][Full Text] [Related]
6. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
Webb MI; Walsby CJ
Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
[TBL] [Abstract][Full Text] [Related]
7. Exploring the coordination chemistry of ruthenium complexes with lysozymes: structural and in-solution studies.
Oszajca M; Flejszar M; Szura A; Dróżdż P; Brindell M; Kurpiewska K
Front Chem; 2024; 12():1371637. PubMed ID: 38638879
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
9. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
[TBL] [Abstract][Full Text] [Related]
10. Unusual structural features in the lysozyme derivative of the tetrakis(acetato)chloridodiruthenium(II,III) complex.
Messori L; Marzo T; Sanches RN; Hanif-Ur-Rehman ; de Oliveira Silva D; Merlino A
Angew Chem Int Ed Engl; 2014 Jun; 53(24):6172-5. PubMed ID: 24796316
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium antimetastatic agents.
Alessio E; Mestroni G; Bergamo A; Sava G
Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
[TBL] [Abstract][Full Text] [Related]
12. Ru-Based CO releasing molecules with azole ligands: interaction with proteins and the CO release mechanism disclosed by X-ray crystallography.
Pontillo N; Ferraro G; Messori L; Tamasi G; Merlino A
Dalton Trans; 2017 Jul; 46(29):9621-9629. PubMed ID: 28702564
[TBL] [Abstract][Full Text] [Related]
13. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Ravera M; Baracco S; Cassino C; Zanello P; Osella D
Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
15. Half-sandwich arene ruthenium(II)-enzyme complex.
McNae IW; Fishburne K; Habtemariam A; Hunter TM; Melchart M; Wang F; Walkinshaw MD; Sadler PJ
Chem Commun (Camb); 2004 Aug; (16):1786-7. PubMed ID: 15306883
[TBL] [Abstract][Full Text] [Related]
16. Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.
Mu C; Chang SW; Prosser KE; Leung AW; Santacruz S; Jang T; Thompson JR; Yapp DT; Warren JJ; Bally MB; Beischlag TV; Walsby CJ
Inorg Chem; 2016 Jan; 55(1):177-90. PubMed ID: 26652771
[TBL] [Abstract][Full Text] [Related]
17. Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin.
Webb MI; Chard RA; Al-Jobory YM; Jones MR; Wong EW; Walsby CJ
Inorg Chem; 2012 Jan; 51(2):954-66. PubMed ID: 22224431
[TBL] [Abstract][Full Text] [Related]
18. On the pH-Modulated Ru-Based Prodrug Activation Mechanism.
Caterino M; Herrmann M; Merlino A; Riccardi C; Montesarchio D; Mroginski MA; Musumeci D; Ruffo F; Paduano L; Hildebrandt P; Kozuch J; Vergara A
Inorg Chem; 2019 Jan; 58(2):1216-1223. PubMed ID: 30614697
[TBL] [Abstract][Full Text] [Related]
19. Protein-mediated disproportionation of Au(i): insights from the structures of adducts of Au(iii) compounds bearing N,N-pyridylbenzimidazole derivatives with lysozyme.
Ferraro G; Giorgio A; Mansour AM; Merlino A
Dalton Trans; 2019 Oct; 48(37):14027-14035. PubMed ID: 31490509
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and X-ray Structural Analysis of the Ruthenium(III) Complex Na[trans-RuCl4(DMSO) (PyrDiaz)], the Diazene Derivative of Antitumor NAMI-Pyr.
Vajs J; Pevec A; Gazvoda M; Urankar D; Goreshnik E; Polanc S; Košmrlj J
Acta Chim Slov; 2017 Dec; 64(4):763-770. PubMed ID: 29318318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
